Cryoport (CYRX) 2 Mar 212020 Q4 Earnings call transcript

Thank you for standing by. This is the conference operator. Welcome to the Cryoport Inc. Year-End 2020 Earnings Call.

As a reminder, all participants are in listen-only mode and the conference is being recorded. will opportunity there ask presentation, the be to an questions. After to I Partner conference would Instructions] turn of now Managing [Operator Fromer, like the Todd over KCSA. to go Please ahead.

Thank operator. you,

today, and These forward-looking statements. future occurring beliefs statements everyone on begin and Before or to performance, our in forward-looking are All on information based would expect developments management's call certain conference the that that remind we we statements not contains are that I available team. assumptions operating this statements. events our to address forward-looking like anticipate or currently management

Our are made. when management these team believes forward-looking reasonable as statements and

undertake However, you update or obligation any statements as otherwise, forward-looking speak or to forward-looking should such revise only required a or as events, statements, information, not except not place law. of new the on as made. result by any any such future when of statements reliance publicly because date whether undue do We

now Jerry, report uncertainties certain Risk present those expectations with in Officer of file the In addition, on and described pleasure Securities in is materially Chief in limited Mr. but our not the historical and forward-looking Executive These Form and turn reports, XX-K Commission. and to floor experience developments yours. annual events XA, Jerrell to over which we to elsewhere from Securities described is filed Exchange from statements It cause time Commission my with to Cryoport. to, are our the the Shelton, differ Exchange other or time call to and Item are risks results, and those Factors, actual and that and include, uncertainties risks subject our projections. could

Thomas We Officer, Corporate Chief Vice ladies Officer, earnings Mr. Relations, and Stefanovich; Thank Heinzen. and Sawicki; and joining our me Scientific With Robert and Dr. Development appreciate Todd. President our you, our Financial of this afternoon Mark is our afternoon, you Good Investor today. Chief call gentlemen.

As to Investor our can XXXX year-end review document and uploaded document under general a the section a reminder, performance Relations the This review recent operational It Events website. provides outlook. found business our section. of our in we financial and have and be Presentations

not encourage go read website chance to have you download you had to it. would and to I it, If the a

closing As execute by acquisitions leverage historic will whom a extend a and that call, the is milestone we move this general not previous client to quarters, conference happened. they therapies transformational results. our will their questions grown significantly strategy we continue our company's on chain to gene year during our breadth relationship our you on we culminating and of your materials. Cryoport, regarding platform two addressing then supply ability with for and all base effectively continuum, in These as ever-expanding which strategic was strengthened provide fourth with to have our irreplaceable a with trust we their the to it core XXXX Cryoport, with we acquisitions. update brief of provide But quarter, global

a the points. convertible by Biological acquisitions chain of financing producer number debt industry. a our the worldwide, temperature-controlled end-to-end million number logistics of CRYOPDP life Biological during We well by The APAC. our for solutions We a network competencies. Group one sciences year. further out the of establishing of a of and We've as established in the foundational centers one acquired acquired and brief stage set Let Solutions, MVE issuing $XXX convertible following of support Cryoport systems to $XXX cryogenic, CRYOPDP build as the further as MVE of provider supply EMEA review of the me $XXX a through total million to Solutions, Blackstone some million, raised accomplishments preferred and

acquisitions, the our located have presence in With expanded XX global XX to two countries. locations we

that of We BMS's Osaka, opened advantage The of and and and our We chain first build relationships us and jointly centers, logistics XXXX. integrated the provides network serving which six, additional grew and launch customers multinational renewed fully global gene center We including power of for to backup will redundancies both Systems initiated extended online and two and also logistics Our support the with when fully Cryoport in risk operational a out cell we for BREYANZI. Novartis CRYOPDP commercial operated services global therapies supply in reduces gives of Gilead. new our customers. Japan. our be number

XXXX investments solutions to proceeds during of and XX highlight Cryoport. coal designed shipper ranges for public launched second our of ended including equivalents short-term the all from completed be temperature crowds pending shipper our to your Certified. we of net led front, of and Leerink of temperature, Morgan patent with XXXX, to Cool. January advance R&D room And line the Elite control scientifically million. support UBS ultra XXXX. and an Stanley, was the proprietary $XXX the expansion million. cash $XX.X and revolutionary and and the shipper On expected in Cryoport shippers and by half cash and underwritten raising offering of We minus Jefferies,

family now supply a a leading platform reinforcing mutually global milestones, leverage companies to the As with temperature-controlled Life provide these further for positioned of is solutions result of strategic sciences. market that chain global Cryoport our

financial new year-over-year XXX% of in continued increased of to for quarter the year million, compared to Our XXXX the $XX.X million strong therapy. increased reflected results revenue of fourth for million, markets solutions, our due a like a growth call And through XXX% I'd full the gene operator to technology and of for momentum to the COVID-XX, XXXX, performance $XX.X $XX.X Total delivered and supply of in full year lines growth the of cell to to we $X.X innovation. the gain goals differentiated focused Cryoport million despite this our the [indiscernible]. compared revenue organic XXXX, We organic true and We suited XXXX, leading and services fourth with on environment, the XX%. to that, the temperature-controlled of especially your XX%. to the total financial chain In quarter of to serve, our gain for summary, questions. with the with The turn sciences surpassed pressures creating of year-over-year XXXX, to products complexities life open for challenges. markets staying these challenges for over business and course

you. Thank

begin now session. Leerink. Souda the Our Instructions] comes from first SVB [Operator We will go ahead. with question Puneet question-and-answer Please

for Hi, and Yes. Thanks Robert. question. the Jerry

sequentially third quarter you it [ph] if the as wasn't and the MVE, could you And is, on step fourth clear from the quarter, there backfill during can the one well? first on So elaborate COVID down any the just contribution elaborate quarter release? was in a from then

continue there very Yes, and a we'll well, expectations, and up is our do Actually Puneet. in step the was met doing quarter so. MVE fourth MVEs. to for

backlog have a the We has transition been nice and very smooth.

In as you terms about XX? - it contribution we is from of know COVID, we XX, support

XX.

It's to COVID. clinical XX. trials XX related

and are some Some re-icing focused therapies are in on a stayed the cures. of And main company role that COVID, Gene or we competency. we some world. some in But a coolness those and we don't we've Cell and and play Therapy of for of are replenishment parts them do

and So COVID involved being any year, here? trials entire on contribution despite in for we up number you the I just expect following of that. a should therapeutics not mean,

minimal. Puneet, sure. be will It won't it will be for It anything be minimal, major

and in this just Okay. guide, point question haven't revenue. you for well the but is of, at provided And total in this terms maybe as is MVE business fairly - time, with CRYOPDP traditionally Robert, as know large I we

consensus, you at higher? combined elaborate wondering, and least if XX% they expect you or - very maybe And $XXX if So the to million if year. CRYOPDP that for forward understand, growing going full just we the MVE separately, year? close us that which are full are for help about be should with could comfortable could Is something us the help the is

Yes, Puneet. I yes, - think thanks,

little in CRYOPDP then potential talked the synergies And together Solutions also we've specific think in MVE terms with growth Biological and the about past, synergies of in created the Systems. a revenue CRYOPDP. for Cryoport and bit with the I it

in growth comfortable think rates rate, that the and we're the obviously So analysts' growth historic general time. for happen will the where of expectations, growth from analysts' year, of I the with terms in change terms in expectations over

we're Cell that some of fruit the So bear profile the throughout And that actions had. Therapy identified. taking and we've is, big to change obviously space the you'll that driver of synergies a see then and Gene the on year they've historically already that the

Cell early of Therapy certainly at discuss giving the guidance terms our and point market the something in around to not forward. and In that that type Medicine a space And stages But Regenerative and time, of of and market space is see Gene as real going revisit matures we'll reason growth. time this give the focus. be basis. on very guidance, what continues the that is that we because giving we're this we'll of grows do to guidance in dynamics At core over the regular

clarifying the Robert, down in margin. question, that Okay. there gross had MVE, in first And just is step I a

in it or gross from fourth out, MVE? quarter gross And sequentially MVE? to wanted due a down the largely there actually for step largely margins? was Is to step-up that just down step margin I So was in that find to third corporate quarter

different. are MVE you look if their profiles margin and think I at CRYOPDP

at at Therapy offering that for lower is revenue the for because profiles can believe area the have high you CRYOPDP Cell legacy which margin margin specifically, lower look down. to which on if And increase legacy kind into solution. table. margins, CRYOPDP, the with higher is drive the par we QX CRYOPDP, opportunities you the Again business, is which performing and of in of and value margin MVE, quality If service that that's past. for been has There example, another slightly and now the brings touch is business that, Gene drive then moving look higher you space, we that - the achieve is

if I hop impacts year? And [ph] grow I'm on got and could this one, into that last expecting then I'll you. any Okay, back queue. Thank the it. if wondering you're

The overall [indiscernible] It impact is revenue. of product. an minimal on be will orphan an

not So impact a notice out a issue. doesn't patient-specific. there is it the in The of of moment doesn't more It's a us. time. to volume look specific it's therapy like obviously have significant this It at

on by a it what And long-term based either others don't they we've in the doing. through issue conference bluebird, heard CEO so of anticipate being and

thanks. Okay,

with comes Jefferies. Couillard next ahead. The question Brandon Please from go

Hey, Good afternoon. thanks.

Brandon. afternoon, Good

I Jerry, And about commercial in believe fourth if at flat, were the you biopharma revenues, those they quarter look sequentially.

that two. just this How last with you expectation? should commercial there, programs item secondly, year think in 'XX? compare line does then growing started how five And to we now of have that your First, about you

that? take you don't Well, why Mark,

Yes.

we're these see of what a fashion. step-wise to going is, operate So all in therapies

to launch they the So the supporting. the three last obviously - years, over geographies patient capacity. of the and products Novartis were of manufacturing They that started early hit transition Kite that in initial absorption their they

rate So growth bit. the on is overall normalized those a

the from to in will as well larger the have year as contribution much is volume They is growth With online this product. middle year. which larger a card of last coming BREYANZI BMS, a

it And as to this versus rate end so of it was we do up year significantly back will anticipate year. what that last commercial pick our the growth overall relates

six Hey, you, is not just therapies, Brandon, five commercial now. correct supporting we're there to

Correct.

Orchard also last year. was approved the is there So end of at there the that out product

products, mean Yes. volume. the both so Orchard But are orphan and they're smaller I the products bluebird

market as we BREYANZI on an the have impact for will [indiscernible] won't they impact, top commercial. So a launch, line bigger obviously have of and but

for thanks that Okay, clarification, Tom.

of built logistics capabilities there? liquid In And in terms the those any which out and pre-existing incremental were Singapore, of investments centers, you centers, locations opened PDP expect the in make course over you logistics other nitrogen about do talk a to have Japan new planned 'XX?

we in being centers logistics new both but more you year, on over is liquid They are course will that to the developing products. then And Houston. Singapore to We the Cryoport you have keep both outfitted next supply those Plains, with we where they handle And this Morris in exactly in two of tell Osaka, operation locations. up our developed premature nitrogen for will new that then but and Brandon, a be location of date Japan relocated - are are, me are we chain development. And it's on locations, all location. to they CRYOPDP. course

Great. I'll hop back Thanks. in queue. the

with D'Silva Andrew ahead. from comes question go next Please The Riley Securities. B.

How support by Hey, provider. and entails historically on example I'm for install larger my everyone's just good entire could for two then it taking over entire logistics thanks manage as afternoon. the entire Cryoport's as you? me and the Gene therapeutics? the interested segment what Therapy. or about do to XXXX of educating parts process were CRYOPDP, sorry a interview we and logistics control just to CRYOGENE, we And and Should the that well, kind actually particularly if start are legacy the vaccine I are think I still questions. relates - you that? business, of therapeutic So hope legacy, a more that - COVID-XX doc. into you going But think that for with about Cell also process vaccines

few. Andy, I want make to a

this all, Sawicki. make Dr. it to I'll comments, a and a question, and of I'll is good First few turn

not COVID off, first focused we are So vaccines. COVID on on and

Cell Therapy within on and sciences. Gene and Our life the focus is

the the massive you be about about vaccines about different. and transferable when though not a project. authorities, is, thinking All sets the are and of you're of the fact not from Cell expect those something ranch the therapies. COVID, significant of totally transferable. then on think dealing used way. That's - And those out. don't our in And least sets the of in about our game. are and way future are COVID. irreplaceable betting coming skill dealing definitely things that market. thinking We're our are states skill with work But in with our the they we with distribution And you're speed We're But or thinking - including on capabilities terms betting get anything matter consulted that's services and number economies manufacturers expensive the could and even our quite vaccines have quite Gene we on

game Our is Gene Therapy. and Cell

to said, do and XX Cell some anything we said, some that support in have you those to of Mark, And Therapy, with cures. I do and Gene that. are add trials those are of As therapeutics

Yes. actually it's Jerry, programs. so XX

yes. XX,

base largely folks And with have our out comes as client our that we the in. come existing have that of support opportunistic relationships well as

our so And product aspect requirements be field. line, for like these volume low of re-icing, it or do the to challenging of Jerry that's maybe basis, not distribution our very high limited something - from in on lanes, a things dry focus said, replenishing margin, vaccine some us or or storage cases many or ask icing not business in is capturing they'll sort some a Like large in clinical may wheelhouse. distribution very drug

on ultra support touch is and high those elements. focus Our requirements

for So cell that's I [indiscernible]. how about guess that and gene therapeutic. therapy, example, is also a where current really

Cell was much us a a a Gene higher. Therapy As had that are be was it distribution storage - there we involved requirement. Therapy likelihood Gene that with… being and yes, will cryogenic and cryogenic of The involved Cell had And and a

you… would What

Sorry.

it's but not So, just Andy. pervasive. been it's And that with ones not the have released,

help can I Maybe you out.

Yes. I that. understand I know, obviously

Tom. This is

those from hospital folks passing away and is keep a to staying treatment the the the trying Gene it's have for Cell time. that in lengthy on Sorry, or but the side on vaccine side side, not COVID

the that's is an - play. our high So the The either vaccine. those side cellular cell But call vaccine seeing you're the the volume therapy. I'll in J&J, mRNA are where or like and traditional vaccine

million useful and you. to questions, deviate you and quarter then hit any for the growth the the and 'XX, fourth material of cadence significant think Okay, then during for our kind there about initiatives consensus progresses been was was $XX of there a in color. [ph] million be that it as should year can Historically, quarter consensus new this quarter, comparing revenue starts almost revenue looking out of we thinking to $XXX on after or of kind of fourth any benefits Thank quarter XXXX previous show at wear should year, the build one-time we year. has just at previous as the And year. the reason kind fourth Is XXXX? and that new for the

And I of our Cryoport revenue the our growth strong with historically to had results had were Yes. in we revenue what expectations and their and QX Look, in Cryoport for and also Thanks, results. overall We MVE strong CRYOGENE. Solutions from think Andy. compared were. to legacy Biological terms Systems satisfied very revenue CRYOPDP we

So a quarter just first that and the is looking at after especially completed. foremost, first transaction

it a think I results. was very good

at of the be ultimately thing of we But can the terms this terms only looking in is, some in that that's growth point. said I analysts. And into say as purchasing. bit revenue XXXX, mind seasonality we're where little comfortable MVE In with of from as may expect in a all of in is should projections look you we seasonality we the of businesses, the have there the revenue there at some terms growth,

established question of know relates Okay. in talking we commercial come really were of year-over-year YESCARTA, just like revenue. previous Squibb's launches this products, the to questions. Bristol-Myers you revenue about primarily from out or starting that should But I expect commercial Last we as should that it are XXXX growth commercial just in KYMRIAH the to most of expect growth from products? YESCARTA and and most

So factors. there's two

So global factor line existing their expansion capacity, one is of an is product right.

a Frederick, look they're So facility in at Maryland, Maryland this you launching if Kite/Gilead, year. new

If for as Stein, announced in a Switzerland year example. new are look in facility well at Novartis, this you Australia launching manufacturing as they partnerships

with So the launches when volume increasing that see then that from will BREYANZI an to the overall standpoint the contribution legacy with the volume-based have product definitively comes obviously most increasing you based associated on capacity online, that revenue obviously being that increase, capacity around new should a the number. evident products combine

question. Good the much. luck you Thank Thanks perfect. taking going for Okay, very forward.

you. Thank

Andy. Thanks,

go from next ROTH with Richard Capital. question ahead. comes Please Baldry The

tools, approach of pro called formas the EBITDA zone one kind integration Thanks. and year of If was a are adjusted three entities the at prior pretty solidly breakeven separate to positive. we looked

much and of for or issues? first we So move by of a before quarter that sort a talk How of company three integration forward you about bit entities resurface had of initiatives or of Thanks. take have current against quickly spending profitability? backdrop, inhibited growth it could the sort as company should there And combined can again? would December a of backwards some kind are sort how profitability the us quarter level that the

it comments few make Hey, a I And want really Rich, turn that's question. good Robert. a then and to to

As as we didn't We in they of for doing. they bought in to them fact, them direction, were companies its of MVE's Cryoport, companies. Within these part I've to if been much very paid they buy there attention before, not matter cetera. they out, and now. Cryoport was what a that, spin-off said for mission. insignificant. support, were for were And et And both CRYOPDP they fact. what a do we companies, CRYOPDP and MVE carrying companies, were part Both look at what were do of had as certainly such out we very will strategic and both that were get and large They're terms important. And able know able we peel are you

And so as Therapy Cryoport, and a advance. in role they forward and march Therapy in the and play Cell Gene Cell will - and we Gene

make in Robert positive it to make and those to moving said ever time, or than that take we direction. all of transitions going the these as performing Mark And does all performed see that, said but you'll a they're and it transitions. will the takes So But upward time earlier, in metrics past. be they've differently

change a markets they not and in see with line more or very either on they accelerates, growth the participating way have because much see heretofore You'll that be Cryoport you'll basis. will a participated limited top in participated margins the rate important

to I'm that, it Robert. turn with So to going

say regulated. when is clarification, a is sciences takes just and life just And it time. Yes. This we it

are forward very aggressively. We actually moving

impact the you up step will and we of at the $XX really of the forward. integration for only year going not includes financials QX If look costs impacted quarter million QX, XXXX, million full and a $X.X that and the also roughly and acquisition in that and for year inventory had

charges, QX, EBITDA. were additional the see So you around EBITDA can $X.X you or you if alone, but for million year look just the breakeven, in at eliminate we the about positive some intangibles, of those for we adjusted that will were

through So, you of that the see pushing bottom profile already to some line.

to mentioned aggressive that profile. think there'll able Jerry growth platform forward But keen I as sure maintaining also with some high think a make going ready similar the we're certainly, for profile. was made and the contribution, drive I be continue on is investments very a to more EBITDA historically MVE very

And just… then

go ahead. Yes,

go you No, please. ahead,

offer talked kind Therapy in On bringing revenues Cryoport CRYOPDP, our extent also growth their the One on focus to higher being some in about the that the and will existing you There on and client XXXX. piggybacking us - margins, space. Gene. broader thing. allowing solution Systems driver Gell be of And base Cell to synergistic a to Gene

accelerating just sort Maybe to you're ways acquired the investors to is term Cell successes entities with space. there finish therapy at point, communicate pulling intermediate into having, and have able be two you'll near-term of or Gene the and them that about the that over

pretty while we you've kind along So break will that at Thanks. rate or a come be can successes we blended away growth any integrating mathematically, difficult of understand that of will path? the to to us down two, that help that the sort metrics it start key had just look

we're just Rich, results, it in. and after business. to way operate metrics working and do you'll of so overall in is family do But the blend we're the the individual in see We of components have certainly going but the environment won't - business, forth. itself and the our careful of also that a that companies. manage mindful we There we

We'll I'm to exactly do not do have but keep mind. the we measures understand what So those with add to to we Robert, anything what you can help be. in that you sure that in do will future, that.

No.

consolidated. understand how have and investors I the to acquisitions think Cryoport they understand progressing we on what that impact want are

to we'll as at and and able means indicators to in that to we that stages, bring acquisitions that information. so do look early these at value that theme want make indicators Especially then to the look well. So understand be will post-acquisition, that provide sure investors drive the certainly we'll Cryoport,

Thanks.

Thank you.

The ahead. David go comes Please with Saxon from next Needham. question

afternoon, taking the combined first of My for business. the Yes, thanks questions. is good just profile and the on margin

I to in expecting getting the expectation a about margin, see that dip help cadence think we guess, the CRYOPDP talked just first, acquisition. can XX%. XX gross and XX%? through that But have targeting your this the of that you're then And to saw You've us the to million longer-term of quarter. obviously you synergies So you on the from margin goal operating cost in

call So we over And the so. path specifically think consensus five or that years should as operating mid-single-digit a think then margin. a I it around to about linear XXXX low in next,

something your in is that So reasonable that's view?

going It we're improvements value market. to client to because that I Yes, of of terms different lower you happen base did time of the on a overall and not is to to companies margin well of based of questions bringing see as next happen appreciate but few that table certainly we'll expect that's think the combined profiles that it already driving be will some there. that margin Look, correctly, as solution we to in up. within the something over it. our a bring each you'll able the quarters, I number the margins framed seek gross the

point margins that's at I time. probably as in can much the on say I as think this

Robert, has also synergies there, that we've there's identified, five million thing, of David years. which other think one in $XXX over I

be a and in achieving that this that While just moving will I to those but in life direction. business are we linear, already mean synergies are there on quarter is of sciences in one nothing not pathway is things the linear,

happening we Cell $XXX Gene will synergy. a part you of into next benefit And thing So also MVE. space moving as will the more you five an see, they same Therapy years and CRYOPDP that from being Inc. that achieve the the some And will see of over in Cryoport million of

to business as point be in this again validated. Robert's to So, everything has

doesn't So instant. say it's still let's be because has particular be Cryoport It Cryoport to CRYOPDP just systems just a systems, working on validated, is with that working going it's to with project. mean

be it to So has validated.

And we're are time. in efficacy so all a It's of that making sciences delivered life sure that controlled, makes that requirement if surety and for is and just the takes sense. conditions

thought in just of past then, our Systems otherwise is in could. in Cryoport What regulated relationship is, quicker client strong and as our does are retention And that it's a Line than since add what. Maybe, the to bring you're CRYOPDP Cryoport client life base strong an we create of though sciences client and terms we've into once that because is example partner, can we very in, then shown the with current base. credit

comment helpful. it, on a Got consensus to any And that's being low mid-single-digit operating margin?

margins again analysts guidance, whole. perspective with we're certainly as think a I my overall, And we're without the Again, From we the improve. assessing are kind to of forward. expecting path our giving comfortable

And it. got then… Okay,

leaders. other market one to though be at thing as David, look should leaders and us continuing market you really

and we the one market. leader initiative is that enough just So needs our always in anticipating share number being market all market were the around an

So look raising. not at share, for market

profitable, and but we're time, the where it's to instantly about will the but all profitability, could we not opportunities keeping We be at raising growth in be and marketplace. any up market profitable share with

about of were That's XX% I helpful. you when it. through said think then their Got sales you bought And distributors. MVE,

benefit would how have you converting or And case, margin the about the talk of can direct that price? that about a plans sales channel? that if is to any of much more So

I nerve sensitive convert the distributor network that is force. have and I don't have don't we sales for system extensive. - mean direct the It's to plans an plans distributor a network into company. extensive

will We replace will not enhance it, it. but we

Okay, very clear.

XXXX this much. so caring And outlook for sorry Thanks potential I and but just talk can BLA MAA the document and approvals? filings about for in for missed you Cryoport if the posted, for

half as sorry, of approved so filed had a last of sitting currently therapies 'XX filings another had year, and second of seven total in six that we supporting. mentioned we XXXX, at were Yes, were last by the all of yes. in that anticipate potentially year, upwards We

thank Great, you.

the to starting cadence is up. pick definitely So

with comes The Johnson Please from next go Stephens. question ahead. Jacob

taking I'm for thanks Hey, the MVE, question if first questions. not on mistaken. Maybe

Can I new products some MVE? launch how growth coming add think me and at will to there could remind you maybe them. these they just were? much from were When what they

refilled you're to from multiple product, XX barriers Well, And to products freezer the the of the that about barrier the temperature fusion. the talking X.XX. minus referring all can never is is And replenish have be were way - that those second down we a you revenue, it has shortly. And new fusion freezer minus is out, our we of liquid disclosed to self-sustaining liquid another powered with of the yet. of impact nitrogen. or And very on coming either that haven't nitrogen size

it. M&A we got, north XXX And of you maybe, acquisitive like Jerry, million you any of just you've something of last add. cash so, if criteria then, and year, could are expect in Got should I you'd think Okay. your remind us M&A, XXXX to capabilities,

expect. mission. that's we and our six out established carry expect our our continue to years and what you ago, Well, you what is should strategy, that six we We continue that mission, to ago, should out years carry

if a they organic takes seller It will a that and bar. a so and be combination of are acquisitions And growth available. robust

be available. customer the to way but the are we partnership discussing can always can of strategic acquisitions acquisition. with when we that map acquisition to will do go have a pipeline time, so And And from all out relationships people all candidates. robust We

is So of can you in about tell we are the that's both as That horizontal. that the acquisition that. much I and kind vertical about looking for as

acquisitions want hopefully them and at to informatics. well the be logistics look we those more make be So strategic accretive well wants to growth already want we'll sense to situation run, that we'll it we where adjacent or expertise could we as at the and company's to at companies spaces to are them and want us a depth. software We'll stay look a to as that profile. acquisitions. on management on look continue with to and propel And tactical What be packaging in and

our strategy. they looking for accretive meet to requirements are we So portfolio our for companies our to out when add carrying healthy

leave the I'll there. it for Thanks it. questions. Got taking

with The ahead. question Markets. go next Please from comes KeyBanc Mike Capital Gokey

the market. Starting less Good a looking Thanks than, on companies at it a like time amount company for the filings is currently seems approved there year, fair today. 'XX without afternoon, Mark, guys. off expected product with this the of the with

how expansion So versus commercial commercial, of supported currently do support you new therapies market kind to expect many your of products?

difficult That's of said, space record track these product lot mean in absolutely you companies approvals. don't have historical of to this ascertain like a a I

based on From nature FDA forward of and more the of with being don't this But offset and obviously can't because that's our that in is and do approvals. to move entities control FDA any we're activities on those the it's to we engage anticipate the However, can perspective, little we that as don't specific ensure really commercialization that for their beyond prepared speculate a need these the they programs inclined support by space. multiple the behalf. you, criticality we I control filing fully and types projects bit we additional

surprised probably some I'd wouldn't absorbed of biopharma. pharma got be add, them larger by Mike, or also I if

the just to or Jerry two, maybe talking launching. but Very And one ship new helpful. then, or

think to in I therapies that be more targeted range. minus gene ADC will the

can or restored new kind acquisition from it is kind customer that temperatures just and the going existing is more Thanks. lower So there? to who of of talk your of clients to are shift it uptake the towards targeted you over while

there and to look from a portfolio be roll-out support and helped Well, it's conjunction a specifically aggressive their nothing in a who kind is market is the took market space actually the where on product to was clients, the was activity that and felt basis. in sufficient one therapy of able interesting gene on designed at of and it that very with who developed the our

so And therapy the market work with vector to we aspects. support actively itself the them space will as and jointly is and product developmental distribution as be both gene designed well viral distribution. into clinical commercial differentiating significant and on The

for time Thanks the Great. guys.

you. Thank

with SVB ahead. Leerink. Souda next go from Please Our again question Puneet comes

Hey, guys.

a clear health MBE of for and efforts on your multiple And launches I split underway thanks I think answered ranges. Just appreciate What them. separately. MVE new a product you on and into taking wasn't the I that is number so number obviously animal that of temperature questions, of

this potentially quick me I'm sustainable animal almost the lower margin on So given the health X business if is and of that, sizable business. from the and nature please Animal is get I Robert mean a you that you. in Thank now this nature business sustainable just wrong is competitive it, longer how how under you did term. MVE and follow-up correct Health million on to wanted

business It's this the where highly way It's is something Puneet, years. business. a been for part of started husbandry. this animal exactly sustainable like Well, MVE in XX is this

very of the of are market. comfortable we that that, dominate - of business We part are and that having business. high an confident share it's extremely the that So part

with comfortable it. we're So

space over think And health Systems on is Yes. will nature of you Cryoport area the MVE animal see relationship activity time that where between one synergy both market. the I to add, just and to based

guys. you, Thank Okay.

Thank you.

to for This session. I turn any to the concludes question-and-answer like over Shelton Jerry would conference the back remarks. closing

for much, all you a pharma It been and animal the I markets. we've been We've position in leadership in Thank them. medicine strongest ever terrific questions. we health, was or in, dialog, And an especially you thank appreciate your biopharma very position XXXX operator. and unrivaled reproductive with of

around best-in-class, of footprint, services those capabilities to in reach team nGenius our unique to life are our we are we and competitive best temperature developing a possible people, specialized redefining our industry, invest that globe the expanded anticipated and the the control needed position have investments that commercial providing as support the advance of moat our medicine enhancing and therapies continuing result market. there are confident we sciences and platform the a continuously be are the our supply our the further for robust broad sciences, will our regenerative today With purpose. extend highly industry I'm come leadership company. clients. in we position and Strategically, to have joining anticipate solutions within As year focus chain delighted us very commercial with To within differentiated industry to scaling to our dedicated business well the organic evening. XXXX. in XXXX acquisitions, life we we growth until increasing agreements. for full a medicine industry XX% We for the meeting the Overall, another growth you and with six way in we us the good the call, performed to as We the that two delivered of a the supporting and company you growth regenerative bid robust with in trials for we XXX XXXX therapy next year. year see want excellent total are traction for indications close the excellent fourth quarter across to thank continue XX% and and

today's concludes This call. conference

have Thank you your And day. lines. participating. disconnect a for may You pleasant